Current Assets
Accounts Receivable
Alnylam Pharmaceuticals Accounts Receivable increased by 13.7% to $883.96M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 111.5%, from $418.04M to $883.96M. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 50.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
An increase relative to sales may signal slowing collections or credit risk, while a decrease suggests efficient cash conversion.
Detailed definition
The total amount of credit extended to customers and channel partners for products sold or services rendered, minus an a...
Peer comparison
Typically scales with revenue growth; however, companies with strong direct-to-consumer channels may have lower receivables relative to those relying on third-party distributors.
Metric ID:
accounts_receivable_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $146.59M | $141.06M | $198.57M | $156.53M | $142.27M | $184.51M | $237.96M | $219.43M | $220.64M | $325.45M | $327.79M | $321.38M | $309.48M | $353.85M | $405.31M | $418.04M | $567.11M | $964.77M | $777.57M | $883.96M |
| QoQ Change | — | -3.8% | +40.8% | -21.2% | -9.1% | +29.7% | +29.0% | -7.8% | +0.5% | +47.5% | +0.7% | -2.0% | -3.7% | +14.3% | +14.5% | +3.1% | +35.7% | +70.1% | -19.4% | +13.7% |
| YoY Change | — | — | — | — | -2.9% | +30.8% | +19.8% | +40.2% | +55.1% | +76.4% | +37.7% | +46.5% | +40.3% | +8.7% | +23.6% | +30.1% | +83.2% | +172.6% | +91.8% | +111.5% |
Range$141.06M – $964.77M
CAGR+46.0%
Avg YoY Growth+54.1%
Median YoY Growth+40.2%
Product Breakdown
| Segment | Q1 '25 | Q2 '25 | Q3 '25 |
|---|---|---|---|
| Net product revenues | $311.93M | $474.70M | $572.80M |
| Total | $418.04M | $567.11M | $964.77M |
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's accounts receivable?
- Alnylam Pharmaceuticals (ALNY) reported accounts receivable of $883.96M in Q1 2026.
- How has Alnylam Pharmaceuticals's accounts receivable changed year-over-year?
- Alnylam Pharmaceuticals's accounts receivable increased by 111.5% year-over-year, from $418.04M to $883.96M.
- What is the long-term trend for Alnylam Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's accounts receivable has grown at a 50.0% compound annual growth rate (CAGR), from $102.41M to $777.57M.
- What does accounts receivable mean?
- The amount of money customers owe the company for products they have already received.